On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma
On-demand, selective IHLRT during Atez/Bev treatment is well tolerated and provides superior and more durable tumor control, particularly in patients achieving an initial objective response.
Authors
- Nozomu Muraishi (ORCID: https://orcid.org/0000-0001-9455-7368)
- Aiko Murayama
- Yuka Hayashi (ORCID: https://orcid.org/0000-0001-8970-1978)
- Kazuto Tajiri (ORCID: https://orcid.org/0000-0002-2373-8601)
- Ichiro Yasuda
- Eiki Ishizaka
Institutions
- University of Toyama (JP)
Publication Details
- Journal
- Cancers
- Published
- 2026-03-21
- DOI
- https://doi.org/10.3390/cancers18061021
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00